Top

Published in:

01-08-2019 | Echocardiography | Cohort Studies

The factors affecting the disease course in Kawasaki disease

Authors: Elif Arslanoglu Aydin, Ilker Ertugrul, Yelda Bilginer, Ezgi Deniz Batu, Hafize Emine Sonmez, Selcan Demir, Zehra Serap Arici, Erdal Sag, Dursun Alehan, Seza Ozen

Published in: Rheumatology International | Issue 8/2019

Abstract

The aim of this study was to review the characteristics of patients with Kawasaki disease (KD) from Turkey and to assess the performance of the Kobayashi score (KS), Harada score (HS), Formosa score (FS), Egami score (ES) and other parameters in predicting intravenous immunoglobulin (IVIG) resistance and coronary artery involvement (CAI) in the Turkish population. Patients who were diagnosed as being in the acute phase of KD at Hacettepe University Faculty of Medicine (Ankara, Turkey) between June 2007 and January 2016 reviewed retrospectively, and those between January 2016 and February 2018 reviewed prospectively, were included in this cohort study. A total of 100 patients with KD were included in this study. Statistical Package for Social Sciences for Windows 22.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. Eighty-five patients (85%) responded to IVIG treatment, whereas 15 (5 female, 10 male) were IVIG resistant. CAI was detected in echocardiography at diagnosis in 31 (31%) (9 female; 22 male) patients. For predicting IVIG resistance, KS, ES, FS, and HS had sensitivity of 82.1%, 26.7%, 30.8%, 69.2% and specificity of 35.7%, 94%, 51.2%, 45.8%, respectively. For the association with CAI occurrence, the sensitivities were 17.2%, 3.3%, 35.7%, 70.4% and the specificities were 78.5%, 88.4%, 49.3%, 49.3% for the aforementioned scores, respectively. The multivariate analysis showed white blood cell (WBC) count [Odd’s ratio (OR) 4.1; 95% confidence interval (CI) 1.26–13.23; p = 0.019] and hematocrit (OR 3.8; 95% CI 1.15–12.4; p = 0.028), as independent predictors of CAI while gamma-glutamyl transferase (GGT) level (OR 5.7; 95% CI 1.73–27.51; p = 0.018) was detected as the only independent predictor of IVIG resistance. This is the first study from Turkey in KD to evaluate the association of the scoring systems for IVIG resistance and CAI. The risk scoring systems in KD did not predict the risk for IVIG resistance and were not associated with CAI in Turkish population.

Available only for authorised users

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M et al (2017) Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 135(17):e927–e999. https://doi.org/10.1161/cir.0000000000000484 CrossRef

Batu ED, Ozen S (2012) Pediatric vasculitis. Curr Rheumatol Rep 14(2):121–129. https://doi.org/10.1007/s11926-011-0232-4 CrossRefPubMed

Eleftheriou D, Batu ED, Ozen S, Brogan PA (2015) Vasculitis in children. Nephrol Dial Transpl 30(Suppl 1):i94–i103. https://doi.org/10.1093/ndt/gfu393 CrossRef

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1–11. https://doi.org/10.1002/art.37715 CrossRefPubMed

Batu ED, Ozen S (2015) Vasculitis: do we know more to classify better? Pediatr Nephrol 30(9):1425–1432. https://doi.org/10.1007/s00467-014-3015-0 CrossRefPubMed

Burns JC, Franco A (2015) The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease. Expert Rev Clin Immunol 11(7):819–825. https://doi.org/10.1586/1744666x.2015.1044980 CrossRefPubMedPubMedCentral

Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R et al (2015) Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open 5(12):e009562. https://doi.org/10.1136/bmjopen-2015-009562 CrossRefPubMedPubMedCentral

Marrani E, Burns JC, Cimaz R (2018) How should we classify Kawasaki disease? Front Immunol 9:2974. https://doi.org/10.3389/fimmu.2018.02974 CrossRefPubMedPubMedCentral

Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M et al (2006) Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 149(2):237–240. https://doi.org/10.1016/j.jpeds.2006.03.050 CrossRefPubMed

10.

Kobayashi T, Inoue Y, Morikawa A (2008) Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease. Nihon Rinsho 66(2):332–337PubMed

11.

Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33(6):805–810CrossRefPubMed

12.

Lin MT, Chang CH, Sun LC, Liu HM, Chang HW, Chen CA et al (2016) Risk factors and derived formosa score for intravenous immunoglobulin unresponsiveness in Taiwanese children with Kawasaki disease. J Formos Med Assoc 115(5):350–355. https://doi.org/10.1016/j.jfma.2015.03.012 CrossRefPubMed

13.

Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD et al (2011) Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 158(5):831–835. https://doi.org/10.1016/j.jpeds.2010.10.031 CrossRefPubMed

14.

Fabi M, Andreozzi L, Corinaldesi E, Bodnar T, Lami F, Cicero C et al (2019) Inability of Asian risk scoring systems to predict intravenous immunoglobulin resistance and coronary lesions in Kawasaki disease in an Italian cohort. Eur J Pediatr 178(3):315–322. https://doi.org/10.1007/s00431-018-3297-5 CrossRefPubMed

15.

Loomba RS, Raskin A, Gudausky TM, Kirkpatrick E (2016) Role of the Egami Score in predicting intravenous immunoglobulin resistance in Kawasaki disease among different ethnicities. Am J Ther 23(6):e1293–e1299. https://doi.org/10.1097/mjt.0000000000000045 CrossRefPubMed

16.

Song R, Yao W, Li X (2017) Efficacy of four scoring systems in predicting intravenous immunoglobulin resistance in children with Kawasaki Disease in a Children’s Hospital in Beijing, North China. J Pediatr 184:120–124. https://doi.org/10.1016/j.jpeds.2016.12.018 CrossRefPubMed

17.

Shin J, Lee H, Eun L (2017) Verification of current risk scores for Kawasaki disease in Korean children. J Korean Med Sci 32(12):1991–1996. https://doi.org/10.3346/jkms.2017.32.12.1991 CrossRefPubMedPubMedCentral

18.

de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B et al (2019) European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease—the SHARE initiative. Rheumatology 58(4):672–682. https://doi.org/10.1093/rheumatology/key344 CrossRefPubMed

19.

Ozen S, Sonmez HE, Demir S (2018) Pediatric forms of vasculitis. Best Pract Res Clin Rheumatol 32(1):137–147. https://doi.org/10.1016/j.berh.2018.09.007 CrossRefPubMed

20.

Ozen S, Batu ED (2018) Vasculitis pathogenesis: can we talk about precision medicine? Front Immunol 9:1892. https://doi.org/10.3389/fimmu.2018.01892 CrossRefPubMedPubMedCentral

21.

Arane K, Mendelsohn K, Mimouni M, Mimouni F, Koren Y, Brik Simon D et al (2018) Japanese scoring systems to predict resistance to intravenous immunoglobulin in Kawasaki disease were unreliable for Caucasian Israeli children. Acta Paediatr 107(12):2179–2184. https://doi.org/10.1111/apa.14418 CrossRefPubMed

22.

Wang Y, Li Z, Hu G, Hao S, Deng X, Huang M et al (2016) Unique molecular patterns uncovered in Kawasaki disease patients with elevated serum gamma glutamyl transferase levels: implications for intravenous immunoglobulin responsiveness. PLoS One 11(12):e0167434. https://doi.org/10.1371/journal.pone.0167434 CrossRefPubMedPubMedCentral

23.

Belay ED, Maddox RA, Holman RC, Curns AT, Ballah K, Schonberger LB (2006) Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994–2003. Pediatr Infect Dis J 25(3):245–249. https://doi.org/10.1097/01.inf.0000202068.30956.16 CrossRefPubMed

24.

Sudo D, Monobe Y, Yashiro M, Sadakane A, Uehara R, Nakamura Y (2010) Case-control study of giant coronary aneurysms due to Kawasaki disease: the 19th nationwide survey. Pediatr Int 52(5):790–794. https://doi.org/10.1111/j.1442-200x.2010.03161.x CrossRefPubMed

25.

Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S (2016) Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. Int J Mol Sci 17(3):278. https://doi.org/10.3390/ijms17030278 CrossRefPubMedPubMedCentral

26.

Clark DE, Denby KJ, Kaufman LM, Fill MA, Piya B, Krishnaswami S et al (2018) Predictors of intravenous immunoglobulin nonresponse and racial disparities in Kawasaki disease. Pediatr Infect Dis J37(12):1227–1234. https://doi.org/10.1097/inf.0000000000002019 CrossRef

27.

Chantasiriwan N, Silvilairat S, Makonkawkeyoon K, Pongprot Y, Sittiwangkul R (2018) Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. Paediatr Int Child Health 38(3):209–212. https://doi.org/10.1080/20469047.2018.1471381 CrossRefPubMed

28.

Jakob A, Whelan J, Kordecki M, Berner R, Stiller B, Arnold R et al (2016) Kawasaki disease in Germany: a prospective, population-based study adjusted for underreporting. Pediatr Infect Dis J 35(2):129–134. https://doi.org/10.1097/inf.0000000000000953 CrossRefPubMed

29.

Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS (2012) Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol. 53(1):4–11. https://doi.org/10.1016/j.pedneo.2011.11.003 CrossRefPubMed

30.

Sag E, Batu ED, Ozen S (2017) Childhood systemic vasculitis. Best Pract Res Clin Rheumatol 31(4):558–575. https://doi.org/10.1016/j.berh.2017.11.009 CrossRefPubMed

31.

Huang SK, Lin MT, Chen HC, Huang SC, Wu MH (2013) Epidemiology of Kawasaki disease: prevalence from national database and future trends projection by system dynamics modeling. J Pediatr 163(1):126–131. https://doi.org/10.1016/j.jpeds.2012.12.011 CrossRefPubMed

32.

Lin MT, Wu MH (2017) The global epidemiology of Kawasaki disease: review and future perspectives. Glob Cardiol Sci Pract 2017(3):201720

Title: The factors affecting the disease course in Kawasaki disease
Authors: Elif Arslanoglu Aydin
Ilker Ertugrul
Yelda Bilginer
Ezgi Deniz Batu
Hafize Emine Sonmez
Selcan Demir
Zehra Serap Arici
Erdal Sag
Dursun Alehan
Seza Ozen
Publication date: 01-08-2019
Publisher: Springer Berlin Heidelberg
Keywords: Echocardiography
Aneurysm
Aneurysm
Echocardiography
Kawasaki Disease
Kawasaki Disease
Kawasaki Disease
Published in: Rheumatology International / Issue 8/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-019-04336-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The factors affecting the disease course in Kawasaki disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2019

Leveraging Google Trends to investigate the global public interest in rheumatoid arthritis

Conventional radiography of the hands and wrists in rheumatoid arthritis. What a rheumatologist should know and how to interpret the radiological findings

Pituitary involvement in patients with granulomatosis with polyangiitis: case series and literature review

Characterization of cell-derived microparticles in synovial fluid and plasma of patients with rheumatoid arthritis

Quantitative power Doppler signal assessment in the subchondral bone region of the metacarpophalangeal joint is an effective predictor of radiographic progression in the hand of rheumatoid arthritis: a pilot study

Correction: Leveraging Google Trends to investigate the global public interest in rheumatoid arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page